Tuesday 13 October 2026
Export CNC’s income statement to Excel — free account
Centene Corporation
CNC Healthcare Healthcare Plans
Centene Corporation’s revenue for fiscal 2025 (year ended December 2025) was $194.8 billion, up 19.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.92%, EPS grew 533.3%, free cash flow grew 116.6% and total debt fell 8.37%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
68.86
1.84
+2.75%
Follow CNC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.16 | 0.08 | 0.10 | 0.09 | |
P/FCF ratio |
3.54 | 2.27 | 4.70 | 5.22 | |
P/Operating CF |
8.83 | 3.69 | 46.43 | 12.92 | |
P/B ratio |
1.40 | 0.75 | 1.01 | 0.83 | |
Price to Tangible BV |
4.17 | 2.56 | 4.35 | 3.27 | |
EV/Sales |
0.10 | 0.04 | 0.09 | 0.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
2.13 | 1.10 | 3.41 | 3.91 | |
EV/FCF |
2.32 | 1.23 | 4.02 | 4.73 | |
Quick Ratio |
1.11 | 1.08 | 1.05 | 1.04 | |
Current Ratio |
1.15 | 1.12 | 1.10 | 1.08 | |
Net Debt/EBITDA |
(7.31) | (3.41) | 2.06 | 0.25 | |
Debt/Assets |
19.40% | 20.17% | 22.67% | 21.42% | |
Debt/Equity |
0.71 | 0.76 | 0.87 | 0.84 | |
Asset Turnover |
2.40 | 2.36 | 2.45 | 2.26 | |
Operating CF/Net income |
3.29 | 2.83 | (0.40) | (0.20) | |
Capex/Depreciation |
(0.58) | (0.67) | (0.65) | (0.67) | |
Interest Coverage |
7.83 | 11.35 | (10.39) | (40.91) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5.79% | 6.80% | 6.78% | 6.33% | |
Intangible Assets out of Total Assets |
0.18 | 0.19 | 0.20 | 0.19 | |
Share Based Compensation of Revenue |
0.11% | 0.13% | 0.12% | 0.10% | |
Graham Net Nets |
(0.43) | (0.91) | (0.81) | (0.97) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.20%) | (40.07%) | (33.07%) | (30.27%) | |
Free Cash Flow Yield |
28.24% | 44.15% | 21.29% | 19.15% | |
Revenue per Share |
108.50 | 101.50 | 100.84 | 101.17 | |
Operating CF per Share |
7.27 | 8.87 | 0.89 | 2.76 | |
Capex per Share |
(0.35) | (0.41) | (0.43) | (0.43) | |
Free Cash Flow per Share |
6.92 | 8.47 | 0.45 | 2.33 | |
Cash per Share |
54.79 | 48.25 | 41.21 | 39.17 | |
Shareholders Equity per Share |
45.83 | 43.70 | 40.63 | 42.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
45.83 | 43.70 | 40.63 | 42.82 | |
Free Cash Flow |
3,416.00 | 4,166.00 | 224.00 | 1,145.00 | |
Working Capital |
5,926.00 | 4,944.00 | 3,652.00 | 3,432.00 | |
Capital Expenditures |
(174.00) | (200.00) | (213.00) | (211.00) | |
Net Current Asset Value |
(13,693.00) | (14,684.00) | (16,344.00) | (16,993.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
19,814.00 | 20,931.00 | 18,909.00 | 20,695.00 | |
Average Payables |
15,742.50 | 15,390.00 | 13,485.00 | 15,106.50 | |
Average Assets |
84,703.50 | 84,109.50 | 79,596.00 | 82,219.00 | |
Average Common Equity |
25,063.00 | 24,754.50 | 23,266.50 | 24,214.00 |
Columns are period end dates